Congratulations, GitLab!!

Congratulations to co-founder and CEO Sid Sijbrandij and the entire GitLab team on their IPO! Here’s to driving software development at scale, and to your ongoing commitment to collaboration, inclusion and transparency. Thank you for creating this powerful platform where everyone can contribute.


Read more on GV News


Photo of Dave Munichiello
Dave Munichiello
& The GV Team

The future is

Latest News

GitLab’s IPO: On Culture, Tech, and Long-Term Thinking

Candice Morgan / October 14, 2021

GV backs founders who transform industries and create new ones

300

active portfolio companies

$5B

under management

48

IPOs

160+

mergers and acquisitions

We've funded more than 500 portfolio companies across all stages and sectors, with an emphasis on enterprise, life sciences, consumer, and frontier technology.


View our portfolio

Tech is in our DNA

Our team of engineers and data scientists work side by side with portfolio companies to solve critical problems and push the frontier of technology.

19

Computer Scientists

10

PhDs

7

MDs

We spun out of Google in 2009

We run as an independent, return-driven fund. Today we have more than $5 billion under management, with Alphabet as our sole limited partner.

2009
Founded as Google Ventures in Mountain View and Boston

First investments:
Silver Spring Networks and Adimab

Hired first design partner
2010
GV opens office in
New York City
2011
Investment #50:
RetailMeNot

Exit:
HomeAway
2012
Investment #100:
Gusto
2013
Investment #200:
Uber

Exits:
Foundation Medicine, The Climate Corp.
2014
London office opens for investment in Europe

Exits:
Nest, Hubspot, OnDeck, Iperian
2015
Google Ventures
becomes GV

Investment #300:
Genomics Medicine Ireland
2016
Exits:
Editas Medicine, Jet.com, CliQr Technologies
2017
Investment #400:
Gritstone Oncology

Exits:
Cloudera, Blue Bottle Coffee
2018
Investment #450:
Lime

Exits:
Flatiron Health, DocuSign, Duo Security
2019
Exits:
Uber, Slack, Shape Security, CTRL-Labs
2020
Exits:
One Medical, ThousandEyes, Lemonade, Relay Therapeutics, Segment, Desktop Metal
2021
Exits:
Sana Biotechnology, Oscar, Clover Health, Vaccitech, 23andMe, Verve Therapeutics, Robinhood, Adagio Therapeutics